Chairman and CEO Alex Lukianov attributes the company’s success to its line of XLIF technology. In addition to 4Q results, NuVasive has reported full-year 2010 financial results. Total revenue for 2010 amounted to $478.2 million, up 29.1 percent from the full-year 2009.
The company received a $2 million settlement from Orthofix during the fourth quarter from to a patent dispute over orthopedic technology. The company also received FDA 510(k) clearance for the Spherx II-Mas deformity spinal system during the fourth quarter.
Read the news release about NuVasive’s financial results.
Read other coverage about company financial reports:
– LDR Announces 77% Sales Growth for U.S. Operations
– Alphatec Spine Reports 4Q Revenue of $46M, 38.4% Increase
– Symmetry Medical Reports 4Q Revenue of $96M, 26% Increase
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
